Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
作者： G J Rustin , A E Nelstrop , P McClean , M F Brady , W P McGuire
DOI: 10.1200/JCO.1996.14.5.1545
关键词:
摘要: PURPOSETo produce definitions based on serial CA 125 levels to measure response of ovarian carcinoma in patients receiving first-line chemotherapy.PATIENTS AND METHODSDefinitions were derived from analysis 277 North Thames Ovary Trial 3. Patient data then incorporated into a computer program and tested against 254 4 458 Gynecologic Oncology Group (GOG) protocol 97. For optimum detection response, three have been combined program. The precise use mathematic logic take account factors such as intervening samples. Response specific treatment has occurred if after two samples there 50% decrease, confirmed by fourth sample (50% response), or decrease over greater than 75% (75% response). final be at least 28 days the previous sample.RESULTSSix hundred twenty 989 considered assessable for ...
sci-hub.se 参考文章(16)
W P McGuire, W J Hoskins, M F Brady, H D Homesley, W T Creasman, M L Berman, H Ball, J S Berek, J Woodward, Assessment of Dose-Intensive Therapy in Suboptimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 13, pp. 1589- 1599 ,(1995) , 10.1200/JCO.1995.13.7.1589
G J Rustin, J N Gennings, A E Nelstrop, H Covarrubias, H E Lambert, K D Bagshawe, Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. Journal of Clinical Oncology. ,vol. 7, pp. 1667- 1671 ,(1989) , 10.1200/JCO.1989.7.11.1667
H E Lambert, G J Rustin, W M Gregory, A E Nelstrop, A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. Journal of Clinical Oncology. ,vol. 11, pp. 440- 448 ,(1993) , 10.1200/JCO.1993.11.3.440
P J Hoskins, K D Swenerton, Oral etoposide is active against platinum-resistant epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 12, pp. 60- 63 ,(1994) , 10.1200/JCO.1994.12.1.60
F Searle, J Boden, J C Lewis, K D Bagshawe, A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization. British Journal of Cancer. ,vol. 44, pp. 137- 144 ,(1981) , 10.1038/BJC.1981.163
G.J.S. Rustin, A. Nelstrop, J. Stilwell, H.E. Lambert, Savings obtained by CA-125 measurements during therapy for ovarian carcinoma European Journal of Cancer. ,vol. 28, pp. 79- 82 ,(1992) , 10.1016/0959-8049(92)90390-N
Ole Mogensen, Prognostic value of CA 125 in advanced ovarian cancer. Gynecologic Oncology. ,vol. 44, pp. 207- 212 ,(1992) , 10.1016/0090-8258(92)90043-I
Laura W. Ng, Howard D. Homesley, Rolland J. Barrett, Charles E. Welander, L. Douglas Case, CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. American Journal of Clinical Oncology. ,vol. 12, pp. 106- 109 ,(1989) , 10.1097/00000421-198904000-00003
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014
Maurie Markman, A Proposal to Use CA-125 to Evaluate Activity of New Antineoplastic Agents in Ovarian Cancer Gynecologic Oncology. ,vol. 51, pp. 297- 298 ,(1993) , 10.1006/GYNO.1993.1292